GleamWall
中文EN

CTMX CytomX Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1501989 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-87.7%
TTM net income YoY-404.9%
TTM EPS YoY-329.6%
Revenue 3-yr CAGR-43.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-676.5%
Net margin-609.0%
FCF margin-363.6%
EBITDA margin—

Returns

ROE-43.6%
ROA-32.7%
ROIC (approx.)-46.3%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets21.9%
Debt / equity0.00x
Current ratio7.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.59x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$76.20M$138.10M
R&D expense$68.73M$83.38M
SG&A expense$29.84M$29.73M
Operating income-$22.36M$25.00M
Pretax income-$17.13M$32.09M
Income tax$238,000$224,000
Net income-$17.37M$31.87M
EBITDA-$21.16M$26.59M
EPS (diluted)——
Weighted avg. shares (diluted)137.94M84.75M
Balance sheet
Cash & equivalents$12.67M$38.05M
Short-term investments$124.39M$62.57M
Receivables$2.01M$3.10M
Current assets$143.92M$107.31M
PP&E, net$1.30M$2.47M
Goodwill$949,000$949,000
Total assets$151.57M$120.53M
Current liabilities$46.62M$85.77M
Total liabilities$52.56M$120.99M
Shareholders' equity$99.01M-$456,000
Shares outstanding170.19M80.10M
Cash flow statement
Operating cash flow-$75.59M-$86.23M
Capital expenditure$220,000$310,000
Free cash flow-$75.81M-$86.54M
Investing cash flow-$59.74M$99.70M
Financing cash flow$110.45M$7.52M
Depreciation & amortization$1.20M$1.60M
Stock-based compensation$6.30M$7.67M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.